Molecular Hybrids of Pyazolo[3,4-]pyridine and Triazole: Design, Synthesis and In Vitro Antibacterial Studies.

Narasimha Rao Bandaru, Parameshwar Makam, Parameswari Akshinthala, Naresh Kumar Katari, Venkanna Banoth, Balakrishna Kolli, Rambabu Gundla
Author Information
  1. Narasimha Rao Bandaru: Department of Chemistry, GITAM School of Science, GITAM Deemed to be University Hyderabad, Rudraram 502329, India.
  2. Parameshwar Makam: Department of Chemistry, School of Applied and Life Sciences, Uttaranchal University, Arcadia Grant, Chandanwari, Premnagar, Dehradun 248007, India.
  3. Parameswari Akshinthala: Department of Science and Humanities, MLR Institute of Technology, Dundigal, Medchal, Hyderabad, Rudraram 500043, India.
  4. Naresh Kumar Katari: Department of Chemistry, GITAM School of Science, GITAM Deemed to be University Hyderabad, Rudraram 502329, India. ORCID
  5. Venkanna Banoth: Department of Biotechnology, University Post Graduate College of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Rudraram 500085, India.
  6. Balakrishna Kolli: Department of Chemistry, GITAM School of Science, GITAM Deemed to be University Hyderabad, Rudraram 502329, India. ORCID
  7. Rambabu Gundla: Department of Chemistry, GITAM School of Science, GITAM Deemed to be University Hyderabad, Rudraram 502329, India.

Abstract

Antimicrobial resistance is on the rise, and there aren't enough new treatments to combat it. This might send the modern world back to the pre-antibiotic age. The molecular hybrids of pyrazolo[3,4-]pyridine and triazole have been designed, synthesized, and analyzed for their drug-like molecule nature and in vitro analyses for their inhibition potentials against and . The compounds and have been identified as the high potential molecules in this series based on in vitro experiments. Compound has zone of inhibition values of 15 ± 0.82 mm and 14 ± 0.7 mm, whilst compound has zone of inhibition values of 18 ± 0.95 mm and 16 ± 0.82 mm against and , respectively. MIC and MIB values for compounds and against and are 0.25 and 0.5, respectively.

Keywords

References

  1. Med Clin North Am. 2018 Sep;102(5):819-829 [PMID: 30126573]
  2. Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26 [PMID: 11259830]
  3. Pharm Res. 1993 Aug;10(8):1123-9 [PMID: 8415396]
  4. Bioorg Med Chem. 2009 Jul 1;17(13):4763-72 [PMID: 19447039]
  5. Eur J Med Chem. 2019 Apr 15;168:357-372 [PMID: 30826511]
  6. J Med Chem. 2004 Dec 2;47(25):6338-48 [PMID: 15566303]
  7. RSC Adv. 2022 Jun 22;12(29):18333-18346 [PMID: 35799934]
  8. Molecules. 2022 Mar 30;27(7): [PMID: 35408636]
  9. J Med Chem. 2002 Jun 6;45(12):2615-23 [PMID: 12036371]
  10. Inorg Chem. 2011 Nov 21;50(22):11715-28 [PMID: 22032295]
  11. Curr Top Med Chem. 2021;21(31):2779-2799 [PMID: 34530712]
  12. Pediatr Infect Dis J. 2013 Apr;32(4):e151-4 [PMID: 23249908]
  13. Nat Rev Drug Discov. 2004 Aug;3(8):711-5 [PMID: 15286737]
  14. Bioorg Med Chem Lett. 2016 Sep 15;26(18):4427-4432 [PMID: 27528432]
  15. Org Biomol Chem. 2010 Nov 21;8(22):5166-73 [PMID: 20848014]
  16. Microb Pathog. 2022 Oct;171:105743 [PMID: 36044936]
  17. Eur J Med Chem. 2019 Oct 15;180:291-309 [PMID: 31319265]
  18. Bioorg Med Chem. 2019 Aug 15;27(16):3511-3531 [PMID: 31300317]
  19. SAR QSAR Environ Res. 2008 Apr-Jun;19(3-4):191-212 [PMID: 18484495]
  20. Adv Drug Deliv Rev. 2017 Jul 1;116:92-99 [PMID: 28554577]
  21. Pharm Res. 1998 Sep;15(9):1490-4 [PMID: 9755906]
  22. Curr Top Med Chem. 2022;22(1):41-63 [PMID: 34766892]
  23. Sci Rep. 2017 Mar 03;7:42717 [PMID: 28256516]
  24. Antibiotics (Basel). 2020 Jun 09;9(6): [PMID: 32526972]
  25. Bioconjug Chem. 2021 Aug 18;32(8):1455-1471 [PMID: 34319077]
  26. Nat Rev Drug Discov. 2011 Mar;10(3):197-208 [PMID: 21358739]
  27. Clin Infect Dis. 2012 Oct;55(7):943-50 [PMID: 22752516]
  28. Curr Opin Crit Care. 2022 Oct 1;28(5):495-504 [PMID: 35942696]
  29. Genome Inform. 2008;20:231-42 [PMID: 19425137]
  30. Int J Mol Sci. 2022 Jul 22;23(15): [PMID: 35897667]
  31. J Mol Evol. 2020 Jan;88(1):26-40 [PMID: 31659373]
  32. Curr Top Med Chem. 2021;21(8):737-752 [PMID: 33655863]
  33. Eur J Med Chem. 2020 Nov 15;206:112686 [PMID: 32795773]
  34. Bioorg Med Chem Lett. 2014 Jul 1;24(13):2905-8 [PMID: 24835633]
  35. Acta Crystallogr Sect E Struct Rep Online. 2014 May 10;70(Pt 6):o650 [PMID: 24940235]
  36. Future Med Chem. 2021 Apr;13(7):643-662 [PMID: 33619989]
  37. Arch Pharm (Weinheim). 2020 Jul;353(7):e2000003 [PMID: 32372473]
  38. AAPS J. 2014 Jan;16(1):65-78 [PMID: 24202722]
  39. Expert Opin Ther Pat. 2013 Mar;23(3):281-98 [PMID: 23289383]
  40. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0044722 [PMID: 35980232]

MeSH Term

Triazoles
Microbial Sensitivity Tests
Staphylococcus aureus
Anti-Bacterial Agents
Pyridines
Klebsiella pneumoniae
Structure-Activity Relationship

Chemicals

Triazoles
Anti-Bacterial Agents
Pyridines

Word Cloud

Created with Highcharts 10.0.00±mmvitroinhibitionvalues4-]pyridinetriazolecompoundszone82respectivelyAntimicrobialresistanceriseenoughnewtreatmentscombatmightsendmodernworldbackpre-antibioticagemolecularhybridspyrazolo[3designedsynthesizedanalyzeddrug-likemoleculenatureanalysespotentialsidentifiedhighpotentialmoleculesseriesbasedexperimentsCompound15147whilstcompound189516MICMIB255MolecularHybridsPyazolo[3Triazole:DesignSynthesisVitroAntibacterialStudiesKpneumoniaePyrazolo[34-b]pyridineSaureusanti-bacterial

Similar Articles

Cited By